Protein kinase 2 (CK2) controls CD4+ T cell effector function in the pathogenesis of colitis.
Ontology highlight
ABSTRACT: Crohn's disease (CD), one of the major forms of inflammatory bowel disease (IBD), is characterized by chronic inflammation of the gastrointestinal tract and associated with aberrant CD4+ T-helper type 1 (Th1) and Th17 responses. Protein kinase 2 (CK2) is a conserved serine-threonine kinase involved in signal transduction pathways, which regulate immune responses. CK2 promotes Th17 cell differentiation and suppresses the generation of Foxp3+ regulatory T cells. The function of CK2 in CD4+ T cells during the pathogenesis of CD is unknown. We utilized the T cell-induced colitis model, transferring CD45RBhi-naive CD4+ T cells from CK2?fl/fl controls and CK2?fl/fldLck-Cre mice into Rag1-/- mice. CD4+ T cells from CK2?fl/fldLck-Cre mice failed to induce wasting disease and significant intestinal inflammation, which was associated with decreased interleukin-17A-positive (IL-17A+), interferon-?-positive (IFN-?+), and double-positive IL-17A+IFN-?+ CD4+ T cells in the spleen and colon. We determined that CK2? regulates CD4+ T cell proliferation through a cell-intrinsic manner. CK2? is also important in controlling CD4+ T cell responses by regulating NFAT2, which is vital for T cell activation and proliferation. Our findings indicate that CK2? contributes to the pathogenesis of colitis by promoting CD4+ T cell proliferation and Th1 and Th17 responses, and that targeting CK2 may be a novel therapeutic treatment for patients with CD.
SUBMITTER: Yang W
PROVIDER: S-EPMC7382987 | biostudies-literature | 2020 Sep
REPOSITORIES: biostudies-literature
ACCESS DATA